NO20032798D0 - Substituerte pyrrolokinoliner og pyridokinoliner som serotonin agonister ogantagonister - Google Patents
Substituerte pyrrolokinoliner og pyridokinoliner som serotonin agonister ogantagonisterInfo
- Publication number
- NO20032798D0 NO20032798D0 NO20032798A NO20032798A NO20032798D0 NO 20032798 D0 NO20032798 D0 NO 20032798D0 NO 20032798 A NO20032798 A NO 20032798A NO 20032798 A NO20032798 A NO 20032798A NO 20032798 D0 NO20032798 D0 NO 20032798D0
- Authority
- NO
- Norway
- Prior art keywords
- disorders
- antagonists
- novel compounds
- serotonin agonists
- pyridoquinolines
- Prior art date
Links
- 239000003420 antiserotonin agent Substances 0.000 title abstract 2
- 239000000952 serotonin receptor agonist Substances 0.000 title abstract 2
- OZKOMUDCMCEDTM-UHFFFAOYSA-N 1,7-phenanthroline Chemical class C1=CC=C2C3=NC=CC=C3C=CC2=N1 OZKOMUDCMCEDTM-UHFFFAOYSA-N 0.000 title 1
- SLHCMPVPVQSTBV-UHFFFAOYSA-N C1=CNC2=C3C=CN=C3C=CC2=C1 Chemical class C1=CNC2=C3C=CN=C3C=CC2=C1 SLHCMPVPVQSTBV-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 208000018522 Gastrointestinal disease Diseases 0.000 abstract 1
- 208000019695 Migraine disease Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 abstract 1
- 208000028017 Psychotic disease Diseases 0.000 abstract 1
- 206010041250 Social phobia Diseases 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- 208000015114 central nervous system disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000004064 dysfunction Effects 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract 1
- 206010027599 migraine Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000004899 motility Effects 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 150000003839 salts Chemical group 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
- 208000012201 sexual and gender identity disease Diseases 0.000 abstract 1
- 208000015891 sexual disease Diseases 0.000 abstract 1
- 208000019116 sleep disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/16—Peri-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/16—Peri-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Child & Adolescent Psychology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Anesthesiology (AREA)
- Nutrition Science (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US25674500P | 2000-12-20 | 2000-12-20 | |
PCT/US2001/049380 WO2002059124A2 (en) | 2000-12-20 | 2001-12-19 | Substituted pyrroloquinolines and pyridoquinolines as serotonin agonists and antagonists |
Publications (2)
Publication Number | Publication Date |
---|---|
NO20032798D0 true NO20032798D0 (no) | 2003-06-19 |
NO20032798L NO20032798L (no) | 2003-08-19 |
Family
ID=22973430
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20032798A NO20032798L (no) | 2000-12-20 | 2003-06-19 | Substituerte pyrrolokinoliner og pyridokinoliner som serotonin agonister ogantagonister |
Country Status (23)
Country | Link |
---|---|
US (1) | US6777406B2 (no) |
EP (1) | EP1399445B9 (no) |
JP (1) | JP4386639B2 (no) |
KR (1) | KR20030070590A (no) |
AT (1) | ATE438646T1 (no) |
AU (1) | AU2002246726B2 (no) |
BG (1) | BG107863A (no) |
BR (1) | BR0116348A (no) |
CA (1) | CA2432181C (no) |
CZ (1) | CZ20031707A3 (no) |
DE (1) | DE60139511D1 (no) |
EE (1) | EE200300303A (no) |
ES (1) | ES2329553T4 (no) |
HU (1) | HUP0303530A3 (no) |
IL (1) | IL156261A0 (no) |
IS (1) | IS6851A (no) |
MX (1) | MXPA03005355A (no) |
NO (1) | NO20032798L (no) |
PL (1) | PL366627A1 (no) |
RU (1) | RU2003121306A (no) |
SK (1) | SK7032003A3 (no) |
WO (1) | WO2002059124A2 (no) |
ZA (1) | ZA200304304B (no) |
Families Citing this family (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6759405B2 (en) | 2000-11-03 | 2004-07-06 | Wyeth | Cycloocta[b][1,4]diazepino[6,7,1-hi]indoles and derivatives |
US6858604B2 (en) | 2000-11-03 | 2005-02-22 | Wyeth | Cyclohepta[b][1,4]diazepino[6,7,1-hi]indoles and derivatives |
AR031202A1 (es) | 2000-11-03 | 2003-09-10 | Wyeth Corp | Ciclopenta(b) (1,4)diazepino(6,7,1-hi) indoles y derivados |
TW200307540A (en) | 2002-04-25 | 2003-12-16 | Wyeth Corp | [1, 4]Diazocino[7, 8, 1-hi] indole derivatives as antipsychotic and antiobesity agents |
TW200307682A (en) | 2002-04-25 | 2003-12-16 | Wyeth Corp | 1,2,3,4,7,8-Hexahydro-6H-[1,4]diazepino[6,7,1-ij]quinoline derivatives as antipsychotic and antiobesity agents |
TWI312781B (en) | 2002-04-25 | 2009-08-01 | [1,4]diazepino[6,7,1-ij]quinoline derivatives as antipsychotic and antiobesity agents | |
CL2004000826A1 (es) | 2003-04-25 | 2005-03-04 | Pfizer | Uso de un agonista para el receptor 5-ht2c para preparar un medicamento util en el tratamiento de la incontinencia urinaria provocada por estres, con la condicion de que el agonista no sea 1-[6-cloro-5-(trifluorometil)-2-piridinil]piperazina (org-129 |
EP2248524A3 (en) | 2004-08-25 | 2011-03-09 | Takeda Pharmaceutical Company Limited | Preventives/remedies for stress urinary incontinence and method of screening the same |
US20070021612A1 (en) * | 2004-11-04 | 2007-01-25 | University Of Notre Dame Du Lac | Processes and compounds for preparing histone deacetylase inhibitors and intermediates thereof |
US7235688B1 (en) | 2004-11-04 | 2007-06-26 | University Of Notre Dame Du Lac | Process for preparing histone deacetylase inhibitors and intermediates thereof |
GT200500317A (es) | 2004-11-05 | 2006-10-27 | Proceso para preparar compuestos de quinolina y productos obtenidos de los mismos | |
AR054849A1 (es) | 2005-07-26 | 2007-07-18 | Wyeth Corp | Diazepinoquinolinas, sintesis de las mismas, e intermediarios para obtenerlas |
TW200734334A (en) * | 2006-01-13 | 2007-09-16 | Wyeth Corp | Treatment of substance abuse |
WO2007112000A2 (en) * | 2006-03-24 | 2007-10-04 | Wyeth | Treatment of pain |
CA2644662A1 (en) * | 2006-03-24 | 2007-10-04 | Wyeth | New therapeutic combinations for the treatment of depression |
EP2018863B9 (en) | 2006-05-16 | 2015-02-18 | Takeda Pharmaceutical Company Limited | Fused heterocyclic compound and use thereof |
CL2008002777A1 (es) * | 2007-09-21 | 2010-01-22 | Wyeth Corp | Metodo de preparacion de compuestos diazepinoquinolinicos quirales por recristalizacion en un sistema de solvente ternario. |
EP2216023A4 (en) | 2007-11-15 | 2013-03-13 | Takeda Pharmaceutical | CONDENSED PYRIDINE DERIVATIVE AND USE THEREOF |
CA2777108A1 (en) | 2009-10-09 | 2011-04-14 | Zafgen Corporation | Sulphone compounds and methods of making and using same |
US20120253036A1 (en) | 2009-12-11 | 2012-10-04 | Yukinori Nagakura | Agent for treating fibromyalgia |
BR112013001613A2 (pt) | 2010-07-22 | 2016-05-24 | Zafgen Inc | compostos tricíclicos e métodos para fazer e usar os mesmos. |
JP6058557B2 (ja) | 2011-01-26 | 2017-01-11 | ザフゲン,インコーポレイテッド | テトラゾール化合物ならびにその作製方法および使用方法 |
AU2012253760B2 (en) | 2011-05-06 | 2016-02-04 | Zafgen, Inc. | Tricyclic pyrazole sulfonamide compounds and methods of making and using same |
EA025526B1 (ru) | 2011-05-06 | 2017-01-30 | Зафджен Инк. | Частично насыщенные трициклические соединения и способы их получения и применения |
KR20140053013A (ko) | 2011-05-06 | 2014-05-07 | 자프겐 인크. | 삼환식 설폰아마이드 화합물 그리고 그의 제조방법 및 그를 이용하는 방법 |
AU2013209723B2 (en) | 2012-01-18 | 2016-11-24 | Zafgen, Inc. | Tricyclic sulfonamide compounds and methods of making and using same |
CA2861381A1 (en) | 2012-01-18 | 2013-07-25 | Zafgen, Inc. | Tricyclic sulfone compounds and methods of making and using same |
EP2925737B1 (en) | 2012-11-05 | 2017-06-14 | Zafgen, Inc. | Tricyclic compounds for use in the treatment and/or control of obesity |
BR112015010225A2 (pt) | 2012-11-05 | 2017-07-11 | Zafgen Inc | compostos tricíclicos e seus métodos de produção e utilização |
CN104918615B (zh) | 2012-11-05 | 2018-10-12 | 扎夫根股份有限公司 | 治疗肝病的方法 |
WO2014078568A1 (en) | 2012-11-14 | 2014-05-22 | The Johns Hopkins University | Methods and compositions for treating schizophrenia |
EP2981266B1 (en) * | 2013-03-04 | 2018-01-03 | Daya CNS LLC | Pentacyclic pyridoindolobenz[b,d]azepine derivatives and uses thereof |
WO2015066344A1 (en) | 2013-11-01 | 2015-05-07 | Arena Pharmaceuticals, Inc. | 5-ht2c receptor agonists and compositions and methods of use |
WO2019131902A1 (ja) | 2017-12-27 | 2019-07-04 | 武田薬品工業株式会社 | 腹圧性尿失禁および便失禁の治療薬 |
CN109897039B (zh) * | 2019-03-13 | 2021-03-30 | 中国科学院化学研究所 | 一种制备吡咯并[3,2,1-ij]喹啉酮化合物的方法 |
JP2024515614A (ja) * | 2021-04-13 | 2024-04-10 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 脳障害を治療するための四環式化合物 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4183936A (en) | 1972-06-19 | 1980-01-15 | Endo Laboratories, Inc. | Pyridopyrrolobenzheterocycles |
US3914421A (en) | 1972-06-19 | 1975-10-21 | Endo Lab | Pyridopyrrolobenzheterocycles for combatting depression |
US4238607A (en) | 1972-06-19 | 1980-12-09 | Endo Laboratories Inc. | Pyridopyrrolo benzheterocycles |
US4115577A (en) | 1972-06-19 | 1978-09-19 | Endo Laboratories, Inc. | Pyridopyrrolobenzheterocycles |
US4013652A (en) | 1972-06-19 | 1977-03-22 | Endo Laboratories, Inc. | Pyridopyrrolobenzoxazine |
US4219550A (en) | 1978-11-09 | 1980-08-26 | E. I. Du Pont De Nemours And Company | Cis- and trans- octahydropyridopyrrolobenzheterocycles |
HUT61548A (en) * | 1990-08-27 | 1993-01-28 | Sandoz Ag | Process for producing indolonaphthyridine derivatives and pharmaceutical compositions comprising such compounds |
-
2001
- 2001-12-19 AT AT01994318T patent/ATE438646T1/de not_active IP Right Cessation
- 2001-12-19 BR BR0116348-5A patent/BR0116348A/pt not_active Application Discontinuation
- 2001-12-19 ES ES01994318T patent/ES2329553T4/es not_active Expired - Lifetime
- 2001-12-19 KR KR10-2003-7008267A patent/KR20030070590A/ko not_active Application Discontinuation
- 2001-12-19 HU HU0303530A patent/HUP0303530A3/hu unknown
- 2001-12-19 EE EEP200300303A patent/EE200300303A/xx unknown
- 2001-12-19 JP JP2002559426A patent/JP4386639B2/ja not_active Expired - Fee Related
- 2001-12-19 CA CA002432181A patent/CA2432181C/en not_active Expired - Fee Related
- 2001-12-19 PL PL01366627A patent/PL366627A1/xx unknown
- 2001-12-19 MX MXPA03005355A patent/MXPA03005355A/es unknown
- 2001-12-19 US US10/026,993 patent/US6777406B2/en not_active Expired - Lifetime
- 2001-12-19 SK SK703-2003A patent/SK7032003A3/sk unknown
- 2001-12-19 DE DE60139511T patent/DE60139511D1/de not_active Expired - Lifetime
- 2001-12-19 WO PCT/US2001/049380 patent/WO2002059124A2/en active IP Right Grant
- 2001-12-19 IL IL15626101A patent/IL156261A0/xx unknown
- 2001-12-19 EP EP01994318A patent/EP1399445B9/en not_active Expired - Lifetime
- 2001-12-19 CZ CZ20031707A patent/CZ20031707A3/cs unknown
- 2001-12-19 AU AU2002246726A patent/AU2002246726B2/en not_active Ceased
- 2001-12-19 RU RU2003121306/04A patent/RU2003121306A/ru not_active Application Discontinuation
-
2003
- 2003-05-30 BG BG107863A patent/BG107863A/xx unknown
- 2003-06-02 ZA ZA200304304A patent/ZA200304304B/en unknown
- 2003-06-18 IS IS6851A patent/IS6851A/is unknown
- 2003-06-19 NO NO20032798A patent/NO20032798L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
CZ20031707A3 (cs) | 2003-11-12 |
US20040092502A1 (en) | 2004-05-13 |
RU2003121306A (ru) | 2005-03-10 |
ATE438646T1 (de) | 2009-08-15 |
BR0116348A (pt) | 2004-11-23 |
EP1399445A2 (en) | 2004-03-24 |
DE60139511D1 (de) | 2009-09-17 |
ES2329553T3 (es) | 2009-11-27 |
KR20030070590A (ko) | 2003-08-30 |
ES2329553T4 (es) | 2010-12-07 |
PL366627A1 (en) | 2005-02-07 |
HUP0303530A3 (en) | 2012-10-29 |
IS6851A (is) | 2003-06-18 |
HUP0303530A2 (hu) | 2004-01-28 |
JP4386639B2 (ja) | 2009-12-16 |
EE200300303A (et) | 2003-12-15 |
ZA200304304B (en) | 2004-09-02 |
SK7032003A3 (en) | 2004-04-06 |
WO2002059124A2 (en) | 2002-08-01 |
CA2432181A1 (en) | 2002-08-01 |
WO2002059124A3 (en) | 2004-01-08 |
NO20032798L (no) | 2003-08-19 |
EP1399445B9 (en) | 2010-07-21 |
US6777406B2 (en) | 2004-08-17 |
IL156261A0 (en) | 2004-01-04 |
JP2004528290A (ja) | 2004-09-16 |
CA2432181C (en) | 2009-11-17 |
EP1399445B1 (en) | 2009-08-05 |
AU2002246726B2 (en) | 2007-03-01 |
BG107863A (en) | 2004-06-30 |
MXPA03005355A (es) | 2004-05-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20032798D0 (no) | Substituerte pyrrolokinoliner og pyridokinoliner som serotonin agonister ogantagonister | |
MXPA03005438A (es) | Pirioindoles substituidos como agonistas y antagonistas de serotonina. | |
MXPA01012914A (es) | Gama-carbolinas fundidas de heterociclo substituido. | |
NO20052728D0 (no) | Substituerte tricykliske gamma-karboliner som serotonin reseptor agonister og antagonister | |
RS20100338A (en) | FLUOROSUPSTITUTIONED CYCLOALCANOINDOLES AND THEIR USE AS AN ANTAGONISTS OF PROSTAGLAND D2 RECEPTORS | |
EA200600071A1 (ru) | Производные n-фенилпиперазина и способы профилактики или лечения заболеваний, связанных с 5ht-рецептором | |
NO20032795L (no) | Substituerte pyrazinokinoksalinderivater som serotonin reseptor agonister og antagonister | |
HUP0303316A2 (hu) | Aril- és amino-aril-szubsztituált szerotoninreceptor agonista és antagonista ligandumok és ezeket tartalmazó gyógyszerkészítmények | |
GB0311349D0 (en) | Therapeutic agents, compositions, preparations and uses | |
EA200501053A1 (ru) | Производные 1,2,4-триаминобензола, пригодные для лечения расстройств центральной нервной системы |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |